摘要
对磷脂酰肌醇3-激酶(Phosphatidyl inositol 3-kinase,PI3K)抑制剂作为抗肿瘤药物的临床研究进展作一综述。PI3K在细胞生长,增殖和凋亡等过程中起重要调节作用,与乳腺癌、卵巢癌、前列腺癌等肿瘤的发生发展密切相关。因此,PI3K已成为很有前途的癌症治疗靶标,超过10多种PI3K抑制剂作为抗肿瘤药物已进入临床研究。
This review focused on the progress in clinical trials testing phosphatidyl inositol 3-kinase inhibitors（ PI3Ki） as anticancer agents. PI3K is involved in various cellular processes and regulates many physiological functions including cell growth,survival,amplification and apoptosis. The PI3K pathway is closely related to the occurrence and development of breast cancer,ovarian cancer,prostate cancer,etc. Therefore targeting PI3Ks is a promising approach for cancer therapy. Clinical trials of more than ten different PI3K inhibitors as anticancer agents are underway.
出处
《海峡药学》
2014年第6期6-13,共8页
Strait Pharmaceutical Journal
